No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 206,837 | 209,121 | 207,972 | 228,065 | 226,705 | 251,365 | 279,586 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 30,780 | 33,470 | 38,777 | 41,088 | 38,034 | 43,042 | 49,708 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Founded in Tokyo in 1887, Nissan Chemical Corporation conducts its diverse business operations both domestically in Japan and across international markets, specializing in four key areas: chemicals, performance materials, agricultural chemicals, and pharmaceuticals. The company's expansive chemical product line includes the adhesive agent MELAMINE, a variety of high-purity chemicals, the urea solution AdBlue, and foundational industrial compounds such as ammonia, sulfuric acid, and nitric acid. Other specialized chemical offerings feature TEPIC (an epoxy compound), Melamine Cyanurate (a salt of melamine and isocyanuric acid), phenylphosphonic acid, and HI-LITE (a chlorinated isocyanurate). Additionally, Nissan Chemical manufactures the health food Nissan Reishi, OPTBEADS (composed of melamine-formaldehyde resin and silica), and FINEOXOCOL (a saturated fatty alcohol and acid). Within its performance materials division, the corporation develops crucial materials for display technologies, semiconductors, and various inorganic applications. Its agricultural chemicals segment supplies a broad range of products, including herbicides, insecticides, and fungicides, utilized on farmlands, golf courses, and public parks. This division also produces active pharmaceutical ingredients for animal antiparasitic medications. In the pharmaceutical sector, Nissan Chemical markets prescription drugs such as LIVALO, which is used to reduce cholesterol, and LANDEL and FINTE, both dual-action calcium channel blockers. Beyond its proprietary pharmaceutical products, the company offers custom manufacturing and process research services for pharmaceutical ingredients. Looking towards future innovation, Nissan Chemical is actively engaged in developing solutions across healthcare, information and communication materials, and environmental and energy materials. The company, which was previously known as Nissan Chemical Industries, Ltd., officially changed its name to Nissan Chemical Corporation in July 2018.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Nissan Chemical Corporation (4021.T)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Founded in Tokyo in 1887, Nissan Chemical Corporation conducts its diverse business operations both domestically in Japan and across international markets, specializing in four key areas: chemicals, performance materials, agricultural chemicals, and pharmaceuticals. The company's expansive chemical product line includes the adhesive agent MELAMINE, a variety of high-purity chemicals, the urea solution AdBlue, and foundational industrial compounds such as ammonia, sulfuric acid, and nitric acid. Other specialized chemical offerings feature TEPIC (an epoxy compound), Melamine Cyanurate (a salt of melamine and isocyanuric acid), phenylphosphonic acid, and HI-LITE (a chlorinated isocyanurate). Additionally, Nissan Chemical manufactures the health food Nissan Reishi, OPTBEADS (composed of melamine-formaldehyde resin and silica), and FINEOXOCOL (a saturated fatty alcohol and acid). Within its performance materials division, the corporation develops crucial materials for display technologies, semiconductors, and various inorganic applications. Its agricultural chemicals segment supplies a broad range of products, including herbicides, insecticides, and fungicides, utilized on farmlands, golf courses, and public parks. This division also produces active pharmaceutical ingredients for animal antiparasitic medications. In the pharmaceutical sector, Nissan Chemical markets prescription drugs such as LIVALO, which is used to reduce cholesterol, and LANDEL and FINTE, both dual-action calcium channel blockers. Beyond its proprietary pharmaceutical products, the company offers custom manufacturing and process research services for pharmaceutical ingredients. Looking towards future innovation, Nissan Chemical is actively engaged in developing solutions across healthcare, information and communication materials, and environmental and energy materials. The company, which was previously known as Nissan Chemical Industries, Ltd., officially changed its name to Nissan Chemical Corporation in July 2018.
